Publications & Posters
Scholarly publications
Spinal Muscular Atrophy
Apitegromab
March 2025
Muscular Dystrophy Association Clinical & Scientific Conference
Efficacy and safety of apitegromab in individuals with type 2 and type 3 spinal muscular atrophy evaluated in the phase 3 SAPPHIRE trial
Immuno-Oncology
SRK-181
November 2024
Society for Immunotherapy of Cancer (SITC) 2024
DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor-resistant advanced cancers
Cardiometabolic Disease
SRK-439
November 2024
ObesityWeek 2024
SRK-439 Selectively Inhibits Myostatin to Promote Healthy Body Composition During Metformin Therapy
Spinal Muscular Atrophy
Apitegromab
October 2024
World Muscle Society Annual Congress
Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: Results from the 48-month TOPAZ study
Spinal Muscular Atrophy
Apitegromab
October 2024
World Muscle Society Annual Congress
Apitegromab in spinal muscular atrophy: Baseline characteristics of participants enrolled in the phase 3 SAPPHIRE study
Spinal Muscular Atrophy
Apitegromab
July 2024
Frontiers in Neurology
